Milestone for Mundipharma EDO as first-in-human solid tumour study begins

Milestone for Mundipharma EDO as first-in-human solid tumour study begins

Mundipharma EDO has begun a US Phase 1/2 clinical study for tinostamustine (EDO-S101) in patients with advanced solid tumours at Stanford University, Cedars Sinai Medical Centre and The Mayo Clinic.

This follows the announcement last year of the first-in-human study for tinostamustine in relapsed/refractory haematological malignancies.

The initial phase of the new study has been designed to determine the safety, tolerability, maximum dose and optimal dosing schedule of tinostamustine as a single agent in patients with solid tumours, who have progressed after at least one line of therapy and no other standard therapy with proven clinical benefit is available.

It will also investigate the pharmacokinetic profile.

The study will then expand to evaluate toxicity and response rates in selected relapsed/refractory solid tumours including: small cell lung cancer; soft tissue sarcoma or non-KIT gastrointestinal stromal tumours; triple negative breast cancer, and ovarian cancer.

Although an effective option for some cancer patients, traditional DNA-damaging therapies have certain limitations which can result in resistance, for example, a failure to gain access to the DNA strands to break them or an inability to counteract the DNA repair mechanisms within cancer cells.

Tinostamustine (EDO-S101) is an AK-DACi (a first-in-class alkylating deacetylase inhibiting molecule) that, in preclinical studies, has been shown to improve access to the DNA strands within cancer cells, break them and counteract damage repair.

Preclinical studies suggest that these complementary and simultaneous modes of action have the potential to overcome resistance.

Preclinical experiments in solid tumours show that tinostamustine exhibits efficacy in most SCLC cell lines, including those that are resistant to doxorubicin. Activity has also been established in preclinical studies for STS, TNBC and ovarian cancer.

Dr. Thomas Mehrling, CEO of EDO, said: “People with advanced solid tumours can become resistant to treatment and often have a relatively poor chance of survival. Breaking through resistance is essential if we are to continue to address unmet needs in oncology.

“This is a key step in the investigation of a first-in-class treatment, which we hope will prove a vital addition for patients with limited current options.”